FLAG-001
Triple Negative Breast Cancer (TNBC)
PreclinicalActive
Key Facts
About FLAG Therapeutics
FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.
View full company profileTherapeutic Areas
Other Triple Negative Breast Cancer (TNBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Membrex™ | Metaclipse Therapeutics | Phase 1 |